CN112715941A

CN112715941A - Composition capable of losing weight and enhancing immunity, product and application thereof

Info

Publication number: CN112715941A
Application number: CN202110126608.9A
Authority: CN
Inventors: 郝守祝; 花汝凤
Original assignee: Weihai Century Beaucamp Seaweed Co
Current assignee: Weihai Century Beaucamp Seaweed Co
Priority date: 2021-01-29
Filing date: 2021-01-29
Publication date: 2021-04-30
Anticipated expiration: 2041-01-29
Also published as: CN112715941B

Abstract

The embodiment of the invention provides a composition capable of losing weight and enhancing immunity, a product and application thereof. The disclosed composition comprises 1-30 parts of seaweed extract, 1-50 parts of L-carnitine and 1-50 parts of xylo-oligosaccharide by mass. The composition provided by the invention can be prepared into various types of products such as drinks, foods, medicines and the like, and has good effects of losing weight and enhancing immunity.

Description

Composition capable of losing weight and enhancing immunity, product and application thereof

Technical Field

The invention relates to a composition capable of losing weight and enhancing immunity, a product and application thereof, and belongs to the field of functional health-care foods.

Background

Obesity is a ubiquitous health problem in countries and groups of people worldwide and is gradually increasing as one of three killers in the human health field. According to WHO estimates, over 4 billion obese patients currently go worldwide, while the overweight population reaches 16 billion, and at least 260 million people die each year due to obesity.

The long-term persistence of obesity results in many health problems, such as hypercholesterolemia, hypertriglyceridemia, insulin resistance, increased peripheral vascular resistance, hyperuricemia, respiratory apnea, type I and type II diabetes, hypertension, coronary heart disease, fatty liver, cirrhosis, and other common conditions in the middle aged and elderly, and obesity is one of the causes of these diseases.

In addition, the obesity changes the dynamic properties of many drugs to affect the therapeutic effect of the drugs, so that special attention needs to be paid to individuation of the drugs for obese people to ensure the safety of the drugs and fully exert the efficacy of the drugs.

With the increasing and youthful trend of the incidence of obesity and hyperlipidemia, the search for safe and effective lipid-lowering and weight-losing ways is a common wish in the medical and health care fields. The current weight-reducing methods are roughly divided into diet control, exercise weight reduction, drug weight reduction, surgery weight reduction and the like. Diet control is weight loss by controlling energy intake, weight gain by reducing food intake and controlling sugar and fat intake; the exercise weight loss is that the body fat-free weight is increased by increasing the heat consumption through the human body exercise, so that the body is firm and healthy, and has good improvement effect on cardiovascular function; drug weight loss is the regulation of body weight by drugs that treat obesity, inhibit energy intake and/or promote energy consumption; surgical weight loss is achieved by, for example, a gastrointestinal surgeon surgically causing the stomach and small intestine to ingest less food and absorb less nutrients than normal.

It is noted that despite the variety of weight loss regimens, there are varying degrees of side effects and complications. Compared with the traditional exercise and diet weight reduction, the medicine weight reduction can achieve the aims of rapidness, effectiveness and difficulty in influencing daily life and solving the obesity problem. Although various lipid-lowering and weight-losing medicines exist in the market at present and new medicines are continuously available, most of the medicines are chemical preparations, some medicines can obviously bring toxic and side effects, such as liver injury with different degrees, and some synthetic medicines have small toxic and side effects but poor effects.

Weight loss can also lead to reduced immunity. The immunity is the ability of the organism to resist external invasion and maintain the stable internal environment, when malnutrition is caused by weight loss and then the immune function of the organism is disordered, or the immune function of the organism is disordered due to excessive movement, the most direct expression is that diseases such as cold, tonsillitis, asthma, diarrhea and the like easily occur, and the diseases can be repeatedly attacked and can be recovered after a long time each time the diseases occur. Therefore, improper weight reduction can easily lead to the symptoms of physical weakness, malnutrition, listlessness, etc. If the condition cannot be solved in time, the life is seriously influenced, and serious diseases are easily induced.

In summary, there is still an objective need for a product that can reduce weight and enhance immunity.

Disclosure of Invention

Embodiments of the present invention provide a composition, an article of manufacture, and applications thereof capable of reducing weight and enhancing immunity, which may overcome one or more of the disadvantages of the related art, and at least partially have the effects of reducing weight and enhancing immunity.

In one aspect of the invention, the composition capable of losing weight and enhancing immunity comprises, by mass, 1-30 parts of seaweed extract, 1-50 parts of L-carnitine and 1-50 parts of xylo-oligosaccharide.

In some embodiments, the algal extract comprises an algal concentrated extract comprising fucoxanthin, the algal concentrated extract comprising one or more of an algal aqueous concentrated powder, an algal alcoholic concentrated powder, and an algal alcoholic concentrated oil.

In some embodiments, the seaweed extract comprises an ethanol extracted concentrated powder of kelp.

In some embodiments, the composition further comprises a white radish extract, wherein the mass part of the white radish extract is 0.2-1 times of the mass part of the xylo-oligosaccharide.

The inventor surprisingly found that the weight-reducing effect is obviously improved after the white radish extract is added.

In some embodiments, the composition further comprises a pH adjusting agent that provides a pH environment for the composition of 4.5 to 6.5.

In another aspect of the present invention, there is provided a product capable of reducing weight and enhancing immunity, comprising the composition according to any one of the preceding embodiments.

In some embodiments, the product is a beverage comprising 1-10% by mass of the composition.

The composition can be added into cold chain product to make beverage, such as fruit juice, ice cream, popsicle, and yogurt with weight reducing effect; the composition can also be made into fruit juice, ice cream, ice sucker, and yogurt with immunity enhancing effect; the food is transported in cold chain, and has low temperature, so that the product has good stability.

Particularly, the yoghourt with the function of losing weight or the yoghourt with the function of enhancing immunity is prepared by using the yoghourt, and the stability of the yoghourt is more favorable due to the cold chain transportation of the yoghourt and the weak acid pH value of the yoghourt. Therefore, the weight-reducing yoghourt prepared by the composition has better effect.

In some embodiments, the beverage is yogurt.

In a further aspect of the present invention, there is provided a use of the composition of any one of the previous embodiments in the preparation of a weight-reducing, immunity-enhancing article.

The inventor surprisingly found that the stability of fucoxanthin in the composition is solved by adding the composition into the yoghourt, and particularly, the stability is stronger for the fucoxanthin extracted from the kelp.

The inventor surprisingly finds that the composition is added into the yoghourt, so that the problem of yoghourt acidification is solved, and the shelf life of the yoghourt is prolonged.

In another aspect of the present invention, there is provided a use of the composition of any of the preceding embodiments to improve the shelf life of yogurt.

The technical solution described in the embodiments of the present invention has at least partially technical improvements in one or more of the following aspects:

1. xylo-oligosaccharide can not be absorbed and digested after entering a human body, so that the increase of blood sugar is prevented, and the increase of body weight caused by high-calorie carbohydrate food is relieved; the L-carnitine can promote the fat transportation efficiency and the oxidative decomposition rate in a human body, promote the fat to be converted into energy, accelerate the fat consumption and play a role in reducing weight; fucoxanthin as active ingredient in Sargassum extract can burn fat cells in human body, and eliminate fat accumulation. The three components are combined and used in synergy in multiple aspects of controlling absorption, fat transformation, burning fat and the like, and have good weight reducing effect.

2. The radix Raphani extract can promote gastrointestinal peristalsis, and partially envelop fucoxanthin in seaweed extract, so as to improve stability in human environment, thereby further promoting weight reducing effect.

3. The weakly acidic environment is favorable for the stability of each component in the composition, inhibits the unpleasant taste of each component, and especially improves the stability of fucoxanthin in the composition, especially for fucoxanthin extracted from kelp. Meanwhile, the composition is particularly suitable for being made into yoghourt products due to the characteristic, and after the composition is added into yoghourt, the problem of yoghourt acidification is solved, and the shelf life of the yoghourt is prolonged.

4. The fucoxanthin can relieve the problems of oxidation and aging disability of various cells in a human body, inhibit the adverse effect of L-carnitine on immunity, selectively proliferate probiotics such as bifidobacterium and lactobacillus by combining xylooligosaccharide, and selectively inhibit the growth of pathogenic bacteria such as escherichia coli and clostridium, thereby playing the effects of maintaining the ecological balance of bacterial colonies in the human body and enhancing the immunity of the human body.

Detailed Description

Various exemplary embodiments of the invention will be described in detail below with reference to specific embodiments. The description of the exemplary embodiments is merely illustrative and is not intended to limit the invention, its application, or uses. The present invention may be embodied in many different forms and is not limited to the embodiments described herein. These embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. It should be noted that: the relative arrangement of parts and steps set forth in these embodiments should be construed as exemplary only and not as limiting unless otherwise specifically noted.

All terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs unless specifically defined otherwise. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.

Techniques, methods, and apparatus known to those of ordinary skill in the relevant art may not be discussed in detail but are intended to be part of the specification where appropriate.

In the following examples, the seaweed extract is prepared by concentrating and extracting seaweed as a raw material, the powder obtained by water extraction and concentration is referred to as water extraction concentrated powder, the powder obtained by concentrating the alcohol extract with beta-cyclodextrin is referred to as alcohol extraction concentrated powder, and the oil obtained by concentrating the alcohol extract with edible oil is referred to as alcohol extraction concentrated oil. The present invention can be applied regardless of the manner in which it is extracted, as long as it contains an effective component of fucoxanthin.

The seaweed extract can be derived from red algae and brown algae, the red algae including Gracilaria, Gelidium, Eucheuma Gelatinosum and thallus Porphyrae, and the brown algae including Sargassum, herba Zosterae Marinae, thallus laminariae and Cyrtymenia Sparsa. The kelp is explained below as an example.

For example, the concentrated powder of kelp extract is a powdered product prepared by pretreating kelp, squeezing or extracting, separating, concentrating, drying, etc.

For example, the concentrated powder of kelp extract is a powdery product prepared by pretreating kelp, juicing or extracting, separating, re-extracting, filtering, blending (adding beta-cyclodextrin), concentrating, press-filtering, drying and the like.

For example, the concentrated oil of kelp alcohol extraction is an oil solution product prepared by pretreating kelp, juicing or extracting, separating, re-extracting, filtering, blending (adding edible vegetable oil), concentrating, extracting, purifying and the like.

In some embodiments of the present invention, the kelp extract used is kelp alcohol extract concentrated powder (e.g., 90% ethanol), and the liquid-material ratio specification of the extraction process is 5: 1-20: 1, for example, can be 12: 1, its particle size is not higher than 80 mesh.

In the examples of the present invention, L-carnitine and xylo-oligosaccharide are commercially available from commercial suppliers.

In the examples of the present invention, the white radish extract can be obtained according to the processes described in the related documents, and the preparation process of the white radish extract common in the art is described as follows, the concentration ratio of which can be generally up to 10: 1-20: 1.

preparation method of white radish extract 1: cleaning radix Raphani, crushing, pulping, squeezing, and adding water continuously during squeezing process until all juice is squeezed out; filtering the juice with porous filter cloth and filter membrane, removing residue, collecting filtrate, filtering repeatedly for 2 times, collecting filtrate, and concentrating with rotary evaporator to obtain radix Raphani extract.

Preparation method 2 of the white radish extract: squeezing radix Raphani, and filtering to obtain clear solution. Adding distilled water into the residue, standing at room temperature in dark for 3 days, filtering supernatant, mixing with the filtrate, standing, filtering, rotary evaporating filtrate, and freeze drying to obtain medicinal powder, i.e. radix Raphani extract.

A method for preparing radix Raphani extract comprises cleaning radix Raphani, cutting into pieces, crushing and squeezing with industrial juicer, adding water and squeezed radix Raphani juice, filtering with 8 layers of gauze to remove residues, and collecting filtrate. And (4) putting the filtered juice into a rotary evaporator for concentration to obtain a crude white radish extract.

Besides the self-preparation, the white radish extract or the high-purity white radish extract effective component powder with the required extraction ratio can be directly purchased from the market.

In the embodiment of the invention, the yoghourt takes milk as a main raw material, and is a fermented dairy product prepared by fermenting 2 or more than 2 kinds of lactic acid bacteria, so that the yoghourt not only has unique flavor and strong palatability, but also has the effects of improving the stomach and intestine and promoting the absorption of calcium and phosphorus.

The shelf life of the yoghourt is short, generally only a few days, and after the yoghourt is normally fermented and solidified, as thalli continue to grow and reproduce in the processes of storage, transportation and sale, the residual lactose is fermented to generate lactic acid, so that the pH value of the yoghourt continues to be reduced, and the sour taste which is unacceptable for consumers can appear.

In the embodiment of the invention, the product can be food, beverage and medicine in various forms, and can be in various types such as solid, powder, liquid, paste and the like according to the preparation process and the added auxiliary materials.

For example, the beverage may be fruit juice, ice cream, yogurt, etc., the food may be ice cream, frozen sucker, etc., and the medicine may be tablet, oral liquid, etc.

In the examples described below, the number in the statistical data represents the 5% level of significance, 1% level of significance, and 0.1% level of significance, as generally indicated in the statistical field.

The compositions described in the examples of the present invention can be understood by reference to the following examples.

Example 1

4 parts of laver water extract concentrated powder, 5 parts of L-carnitine and 6 parts of xylo-oligosaccharide, and uniformly mixing.

Example 2

10 parts of laver alcohol extract concentrated powder, 1 part of L-carnitine and 5 parts of xylo-oligosaccharide, and uniformly mixing.

Example 3

2 parts of laver alcohol-extracted concentrated oil, 40 parts of L-carnitine and 40 parts of xylo-oligosaccharide, mixing the L-carnitine and the xylo-oligosaccharide uniformly, stirring, adding the laver alcohol-extracted concentrated oil into the mixture in a spraying manner, and mixing uniformly to obtain the laver alcohol-extracted concentrated oil.

Example 4

4 parts of sargassum fusiforme water extract concentrated powder, 5 parts of L-carnitine and 6 parts of xylo-oligosaccharide, and uniformly mixing.

Example 5

10 parts of sargassum fusiforme alcohol extract concentrated powder, 1 part of L-carnitine and 5 parts of xylo-oligosaccharide, and the components are uniformly mixed.

Example 6

2 parts of sargassum fusiforme alcohol-extracted concentrated oil, 40 parts of L-carnitine and 40 parts of xylo-oligosaccharide, mixing the L-carnitine and the xylo-oligosaccharide uniformly, stirring, adding the sargassum fusiforme alcohol-extracted concentrated oil into the mixture in a spraying manner, and mixing uniformly to obtain the sargassum fusiforme alcohol-extracted concentrated oil.

Example 7

5 parts of kelp water extract concentrated powder, 5 parts of L-carnitine and 5 parts of xylo-oligosaccharide, and uniformly mixing.

Example 8

10 parts of kelp alcohol extract concentrated powder, 5 parts of L-carnitine and 1 part of xylo-oligosaccharide, and uniformly mixing.

Example 9

10 parts of kelp alcohol extract concentrated powder, 5 parts of L-carnitine, 1 part of xylo-oligosaccharide and 0.5 part of white radish extract, and uniformly mixing.

Example 10

1 part of kelp alcohol extract concentrated oil, 50 parts of L-carnitine and 50 parts of xylo-oligosaccharide, mixing the L-carnitine and the xylo-oligosaccharide uniformly, stirring, adding the kelp alcohol extract concentrated oil into the mixture in a spraying manner, and mixing uniformly to obtain the kelp alcohol extract concentrated oil.

Example 11

1 part of fucoxanthin, 2 parts of L-carnitine and 3 parts of xylo-oligosaccharide, and uniformly mixing.

Example 12

1 part of fucoxanthin, 2 parts of L-carnitine, 3 parts of xylo-oligosaccharide and 2 parts of white radish extract, and uniformly mixing.

The composition of the articles described in the examples of the present invention may be understood by reference to the following examples.

Example 13

Example 1-12 any one of the compositions 1 part, added to a frozen stick formulation to form 100 parts by weight of a frozen stick.

Example 14

Example 1 to 12, to 100 parts by mass of ice cream bar ingredients.

Example 15

Example 1-12 any one of the compositions 1 part, is added to an ice cream formulation to form 100 parts by weight of ice cream.

Example 16

Example 1-12 any of the compositions 2 parts, added to fruit juice and mixed to obtain 100 parts by weight of fruit juice beverage.

Example 17

Example 1-12 any of the compositions 5 parts, added to yogurt to produce 100 parts by weight of yogurt.

Example 18

Example 1-12 any of the compositions 8 parts, added to yogurt to produce 100 parts by weight of yogurt.

Example 19

Example 1-12 any of the compositions 10 parts, adding into common biscuit raw materials to make 100 parts by weight of biscuit

Example 20

Example 1-12 any of the compositions 10 parts, added to bread ingredients to make 100 parts by weight of bread.

Example 21

The prescription of the coating liquid is as follows:

taking the composition of the example 8, lactose, microcrystalline cellulose and croscarmellose sodium, sieving with a 30-mesh sieve, crushing, and respectively sieving silica gel micropowder and magnesium stearate with a 100-mesh sieve for later use;

weighing the composition in the formula amount of the example 8, adding the croscarmellose sodium, the microcrystalline cellulose and the lactose by an equivalent progressive method, and uniformly mixing; adding magnesium stearate and aerosil according to the prescription amount, and mixing uniformly.

Shallow concave punching and pressing tablets with phi of 8mm are adopted, the theoretical filling amount of particles is 160mg, and the hardness is 6kg +/-2 kg;

adding the coating powder of the prescription amount into a proper amount of purified water while stirring, stirring for 1 hour until a uniform suspension is formed, coating a film, and increasing the weight by 3-4%.

And inspecting and packaging finished products.

Example 22

Example 1-12 any of the compositions 10 parts, added to common adjuvants of granules to make 100 parts by weight of granules

Example 23

The pre-treated composition of example 9, dibasic calcium phosphate, sodium lauryl sulfate, crospovidone (internal addition) were weighed out and mixed as prescribed.

Mixing the raw materials and adjuvants uniformly, adding appropriate amount of water to make soft, granulating with 30 mesh sieve, and drying in oven at 50 deg.C.

Sieving the dry granules with a 30-mesh sieve, granulating, adding crospovidone (additional part) and magnesium stearate according to the prescription amount, and mixing.

Measuring the content of the mixed granules, and loading the granules into No. 1 capsule or bag to obtain granule according to the measurement result to make the content of the capsule be 100%.

The capsules are packaged in time, and the packaging should be moisture-proof and light-proof.

Checking according to quality standard of the product.

The samples were stored in dry and cool places.

Example 24

Example 1-12 any composition 7 parts, added to the preparation of oral liquid adjuvants to make 100 parts by weight of oral liquid.

Comparative example 1: fucoxanthin single product

Comparative example 2: l-carnitine single product

Comparative example 3: a composition for reducing fat and weight comprising: 3g of xylo-oligosaccharide, 1g of inulin, 1.5g of isomalto-oligosaccharide, 1.5g of fructo-oligosaccharide, 1g of fruit and vegetable powder, 1g of L-carnitine, 20 hundred million strains of lactobacillus plantarum, 5 hundred million strains of lactobacillus rhamnosus and 25 hundred million strains of lactobacillus johnsonii.

In order to illustrate the effects of the compositions of the present invention in the related art, the applicant conducted the following tests.

Test example 1: research on effect of composition in embodiment of the invention on enhancing immunity

Experimental animals: female ICR mice of clean grade, body weight (20 ± 2) g, were used for the experiments.

Detecting environmental conditions, wherein the temperature range is 20-25 ℃, and the relative humidity is 40-70%. Mice were acclimated in the animal house environment for 3d prior to the experiment.

Experimental grouping and period: each test item is provided with an experimental group and a negative control group with different dosages, a group of comparative example 1 and a group of comparative example 2, wherein each group comprises 10 animals, wherein the administration dosage of the experimental group is respectively designed into a low dosage group (0.13 g/kg), a medium dosage group (0.27 g/kg) and a high dosage group (0.80 g/kg) according to 5 times, 10 times and 30 times of the human body recommended dosage of 1.6g/d (60 kg) respectively, the comparative example group is administered with the dosage which is equal to the dosage of the experimental group, all groups are orally administered with samples with different dosages, the gavage volume is 0.1ml/10g of body weight, one time/d is counted for 30 d; the negative group was given the same volume of saline.

The experimental group is exemplified by example 8 of the present invention.

Spleen lymphocyte cell transformation experiment MTT method: on day 30 of the experiment, each mouse was aseptically harvested and placed in a dish containing an appropriate amount of sterile Hanks' solution, and the spleen was gently triturated with forceps to make a single cell suspension. The spleens were either filtered through a 200 mesh screen or triturated with 4 layers of gauze and washed 2 times with Hanks' solution and centrifuged 10min (1000 r/min) each time. Then suspending the cellsThe number of viable cells (more than 95%) was counted by staining with Taichol blue in 1ml of complete culture medium, and the cell concentration was adjusted to 3X 10⁶One per ml. The cell suspension was added to a 24-well plate in two wells, 1ml per well, 75. mu.l ConA solution (equivalent to 7.5. mu.g/ml) was added to one well, and 5% CO was added to the other well as a control₂，37℃ CO₂Culturing in an incubator for 72 h.

4 hours before the end of the culture, 0.7ml of the supernatant was gently aspirated from each well, and 0.7ml of calf serum-free RPMI1640 culture medium was added thereto together with 50. mu.l/well of MTT (5 mg/ml), and the culture was continued for 4 hours. After the culture is finished, 1ml of acidic isopropanol is added into each hole, and the mixture is uniformly blown and beaten to ensure that the purple crystals are completely dissolved. The solution was then transferred into a cuvette and the OD value was determined at a wavelength of 570nm using a 721 spectrophotometer. The optical density of the ConA wells subtracted by the optical density of the ConA wells represents the proliferative capacity of the lymphocytes.

Determination of serum hemolysin: on the 25 th day of the experiment, each mouse was immunized by injecting 0.2ml of 2% (V/V) packed Sheep Red Blood Cell (SRBC) suspension into the abdomen. After 5 days, blood is taken and centrifuged, serum is collected, the serum is diluted by multiple times by using physiological saline, the blood is incubated for 3 hours in an incubator at 37 ℃, the hemagglutination degree is observed, and the antibody product number is calculated.

Phagocytic capacity of macrophages: 30min before sacrifice, 1.0ml of 20% (V/V) chicken red blood cell suspension is injected into the abdomen of each mouse, 2ml of normal saline is injected after sacrifice, the abdominal cavity liquid drop is taken, incubated for 30min at 37 ℃ in an incubator, fixed, dyed, examined by a microscope, 100 macrophages are counted, and the phagocytosis rate is calculated.

The test results are described below:

lymphocyte proliferation potency: the effect of the compositions of the present examples on ConA-induced splenic lymphocyte proliferation capacity in mice is shown in table 1. The test result shows that the composition provided by the embodiment of the invention can obviously improve the proliferative capacity of spleen lymphocytes, is obviously superior to a single product of fucoxanthin, and the single use of L-carnitine does not contribute to improving the immunity.

TABLE 1 Effect of mouse spleen lymphocyte proliferation Capacity (g/kg)

Group of	Dosage to be administered	OD difference value
			Low dose group	0.13	0.324±0.014^**
Middle dose group	0.27	0.396±0.022^**
			High dose group	0.80	0.486±0.127^**
Comparative example 1 group	0.27	0.224±0.033^**
			Comparative example 2 group	0.27	0.183±0.018^*
Negative control group	-	0.195±0.021

Serum hemolysin: the effect of the examples of the present invention on mouse serum hemolysin is shown in table 2. The test result shows that the composition provided by the embodiment of the invention can obviously improve the mouse serum hemolysin antibody accumulation level compared with a negative control group, is obviously superior to a fucoxanthin single product, and does not contribute to improving the immunity by singly using the L-carnitine.

TABLE 2 Effect of mouse serum hemolysin (g/kg)

Group of	Dosage to be administered	Number of antibody products
			Low dose group	0.13	280.4±14.2^**
Middle dose group	0.27	293.6±22.1^**
			High dose group	0.80	316.7±32.5^**
Comparative example 1 group	0.27	250.1±33.2^**
			Comparative example 2 group	0.27	189.7±18.5
Negative control group	-	220.3±18.1

Phagocytic capacity of macrophages: the effect of the compositions of the present invention on phagocytosis of chicken red blood cells by macrophages in the mouse peritoneal cavity is shown in table 3. The test result shows that the composition provided by the embodiment of the invention can improve the phagocytosis rate of chicken red blood cells phagocytosed by abdominal macrophages of splenic mice, is obviously superior to a fucoxanthin single product, and does not contribute to improving the immunity by singly using L-carnitine.

TABLE 3 Effect of phagocytosis of chicken erythrocytes by mouse peritoneal macrophages [ g/kg (%) ]

Group of	Dosage to be administered	Rate of phagocytosis
			Low dose group	0.13	45.8±6.2^**
Middle dose group	0.27	48.6±5.1^**
			High dose group	0.80	49.5±6.7^**
Comparative example 1 group	0.27	15.1±3.2^**
			Comparative example 2 group	0.27	3.92±0.13
Negative control group	-	4.28±0.72

According to the relevant regulations in "test and evaluation of health food" (2003 edition), "judgment of immunity enhancing function: the test results show that the composition of the embodiment of the invention can at least improve the proliferation capacity of splenic lymphocytes of mice, the antibody accumulation level of serum hemolysin of the mice and the phagocytosis rate of chicken erythrocytes phagocytized by macrophages in abdominal cavities of the mice, and has the effect of enhancing the immunity based on the specification.

Test example 2: study on the effect of the composition of the embodiment on weight reduction

Experimental animals: male SD rats of similar body weight were selected, 10 per group.

The high calorie model feed is prepared by mixing basic feed and nutritional feed.

Basic feed: 20% of barley flour, 10% of dehydrated vegetables, 20% of bean flour, 1% of yeast, 5% of bone meal, 16% of corn flour, 16% of wheat bran, 10% of fish meal and 2% of salt.

The nutrient feed comprises: the following nutritional feeds are added into each 100g of basic feed: 10g of milk powder, 10g of lard oil, 1 egg and 250g of fresh soybean sprouts.

The amount of feed was 13g per mouse per day in weeks 1 and 2, and increased by 2g per week to week 6 (23 g). The feed is supplied for 2 times every day, and is not added after being eaten.

After feeding weaned rats with the high-fat high-nutrition feed for 45 days, the weight of the weaned rats is nearly doubled (100g) compared with the weight of the same-age rats fed with the common feed, which indicates that the molding is successful.

After the molding is finished, 60 obesity-sensitive rats are randomly divided into 6 groups according to the body weight, and each group is 10, namely a model control group, an example 8 group, an example 9 group, a comparative example 1 group, a comparative example 2 group, a comparative example 3 group and a blank control group. The food intake, food amount scattered, and food remaining amount were recorded every week, and the body weight was weighed 1 time. The example 8 group, the example 9 group, the comparative example 1 group, the comparative example 2 group and the comparative example 3 group were fed with 5mg of each daily dose incorporated into a basal diet. The blank control group was fed with only ordinary feed, the model control group was fed with high calorie model feed, and the dose of each group was 25mg/kg rat body weight for 30 days, and the test results are shown in table 4.

TABLE 4 weight and fat content changes in vivo (fat pad around testis and kidney)

As can be seen from the above, the composition provided by the embodiment of the invention has a remarkable weight-losing effect, is obviously superior to the existing control products, shows that the scientific matching and combination of the components are synergistic in various aspects such as absorption control, fat transformation control, fat burning control and the like, and has a good weight-losing effect.

The above data also show that the composition of the present invention effectively improves and enhances the weight-reducing effect by further adding the white radish extract.

Test example 3: research on improving shelf life of yoghourt by using composition provided by embodiment of the invention

A certain brand of low-temperature flavored yogurt (with the quality guarantee period of 21 d) sold in the market is added with the composition of the example 11 according to the mass ratio of 5%, 10 bottles of the processed yogurt and 10 bottles of the brand of low-temperature flavored yogurt without the composition of the example are respectively placed in a refrigeration environment at 5 ℃, and the viscosity and the acidity are measured at 30 days, 40 days, 50 days and 60 days.

The viscosity measurement conditions were: brookfield LVDV-II +, S63,12rpm, 10S, 25 ℃ was used;

two groups of 20 common consumers are selected, and 10 persons in each group respectively taste the processed yoghurt finished product and the original yoghurt product and provide evaluation results.

TABLE 5 viscosity change (mPa. multidot.S) at different times

Group of samples	30d	40d	50d	60d
					Processed yogurt set	4008	4110	4030	4000
Original yogurt set	3510	3221	2975	2761

TABLE 6 Gill-Nell acidity Change at different times (° T)

Group of samples	30d	40d	50d	60d
					Processed yogurt set	73	73	74	74
Original yogurt set	77	79	88	Degeneration and meaninglessness

On the aspect of sensory flavor evaluation of users, the original yogurt group is evaluated in 30d and similar to the processed yogurt group in 30d, and the basic characteristics of rich flavor, fine state, smooth mouthfeel and good swallowing feeling of the yogurt product are basically kept; at 40d, the processed yogurt group still maintains the good characteristics of the yogurt product, and users evaluate that the fermented flavor is rich, the state is uniform and fine, the mouthfeel is mellow and smooth, the drinking has the creamy feeling and the swallowing feeling is good, the original yogurt group has prominent fermented flavor, relatively uniform state, mellow mouthfeel, slightly astringent feeling and not smooth enough; at 50 days, the processed yogurt group still maintains the good characteristics of the yogurt product, the user evaluates that the fermented flavor is rich, the state is uniform and fine, the mouthfeel is mellow and smooth, the drinking has creamy and good swallowing feeling, and the user evaluation of the original yogurt group is obviously reduced, mainly manifested by insufficient prominence of the fermented flavor, sticky mouthfeel, obvious colloidal feeling and difficult swallowing; at 60d, the original yogurt group product user indicates that the product is obviously deteriorated and the flavor cannot be drunk, the processed yogurt group user evaluates that the cream feeling is reduced and slightly sticky, and the other evaluations are unchanged.

As can be seen from the above, the composition of the invention is added into the yoghourt, so that the shelf life of the yoghourt is obviously prolonged, and the flavor of the yoghourt is favorably maintained for a longer time.

Experimental example 4 this example composition was added to yogurt to increase the stability of fucoxanthin.

The fucoxanthin content of the composition of example 8 was measured, and 10 parts of the composition of example 8 was added to 90 parts of yogurt (pH about 6). The contents were measured and the above measured contents were the contents in the powder and in the yoghurt for 0 day, respectively.

The contents of 5 days, 10 days and 20 days (the powder was left at room temperature and the yogurt was left at 4 ℃ or lower according to the storage condition of the yogurt) in the yogurt and in the powder were calculated as 100% in each of 5 days, 10 days and 20 days, respectively, based on the measured content of 0 day, and the results were as follows:

TABLE 6 changes in fucoxanthin content at different times

	Day 0	5 days	10 days	20 days
					Fucoxanthin in powder	100.0%	90.12%	80.52%	60.42%
Fucoxanthin in sour milk	100.0%	95.23%	90.89%	81.57%

From the above results, it is seen that the stability of haloxanthin in yoghurt is much better than in powder.

Claims

1. A composition capable of losing weight and enhancing immunity is characterized by comprising 1-30 parts of seaweed extract, 1-50 parts of L-carnitine and 1-50 parts of xylo-oligosaccharide by mass.

2. The composition as claimed in claim 1, wherein the seaweed extract comprises a concentrated seaweed extract containing fucoxanthin, and the concentrated seaweed extract comprises one or more of concentrated seaweed water extract powder, concentrated seaweed alcohol extract powder, and concentrated seaweed alcohol extract oil.

3. The composition as claimed in claim 2, wherein the seaweed extract comprises an ethanol-extracted concentrated powder of kelp.

4. The composition of claim 1, further comprising a white radish extract, wherein the white radish extract is 0.2-1 times of the xylo-oligosaccharide in parts by weight.

5. The composition of claim 1, further comprising a pH adjusting agent, wherein the pH adjusting agent provides a pH environment of the composition of 4.5 to 6.5.

6. A product capable of reducing weight and enhancing immunity comprising a composition according to any one of claims 1 to 5.

7. The product according to claim 6, wherein the product is a drink comprising 1-10% by mass of the composition.

8. The product of claim 7, wherein the beverage is yogurt.

9. Use of a composition according to any one of claims 1 to 5 for the preparation of a product for weight loss and for enhancing immunity.

10. Use of a composition according to any of claims 1 to 5 for improving the shelf life of yoghurt.